Homepage

Future of Chair in Global Health secured with £5 million gift

The University of Oxford’s commitment to tackling major global health challenges has been strengthened following the endowment of a chair in global health and clinical development. The new permanent post was made possible by a £5 million donation from Brazilian healthcare organisation SAIL for Health.

First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)

Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).

First in-human trials commence for CCHF vaccine

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

University of Oxford partners with CEPI to counter the threat of future pandemics

The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.

Director of Global Operations at OVG recognised in the King’s Birthday Honours 2023

Dr Parvinder Aley, Director of Global Operations at the Oxford Vaccine Group, has been recognised and celebrated in the 2023 King’s Birthday Honours list. Dr Aley has been appointed an Officer of the Order of the British Empire (OBE) for services to vaccination during the COVID-19 pandemic.

Professor Sir Andrew Pollard reveals unique insights into the world of science in a new podcast

Oxford Vaccine Group and Pandemic Sciences Institute’s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.

Britain’s Covid research led the world – why have our clinical trials fallen off a cliff?

Pressures on the NHS, a lack of doctors and post-Brexit delays are hampering our ability to develop cutting-edge drugs.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Take part in a clinical trial – see a list of all the trials we are currently recruiting to.

Child being vaccinated

Non-COVID research statement

The Oxford Vaccine Group will be continuing with some of our non-COVID research, particularly our paediatric studies, during the COVID-19 pandemic. This is because as part of these studies we give babies their routine primary immunisations on behalf of their GPs. This reduces the administrative burden on the NHS, allowing them to free up capacity and prioritise their workload to be focused on doing what is necessary to manage the response to the COVID-19 pandemic. The participants also benefit from having the vaccines in the safety of their homes or a convenient location.

Vaccine Knowledge

The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases.

See more

Research

Vaccines are a key component of global health policy and are essential in the defence of the health of young children. Our research focuses on the development and evaluation of new and improved vaccines.

Explore

Events and Training

We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.

Learn

Get involved

There are a number of ways in which you can get involved in our research, inform our research and find out more about our work. To find out more about any of these options, follow the link below.

Participate

Latest publications

Early transcriptional responses to human enteric fever challenge.
Journal article

Barton A. et al, (2023), Infect Immun
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint

Jakobsen NA. et al, (2023)
Motivations for paediatric vaccine trial participation.
Journal article

Hillson K. et al, (2023), Trials, 24
Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study.
Journal article

Cardona RSB. et al, (2023), Vaccine, 41, 5769 - 5774
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Journal article

Neale I. et al, (2023), mBio

National Immunisation Schedule Evaluation Consortium

OVG is part of the National Immunisation Schedule Evaluation Consortium; a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency, with a brief of conducting clinical research relevant to UK immunisation policy

More about NISEC

We’ve made a vaccine, now you can make the difference

We’ve heard about how effective vaccines are, but what do we need for them to have the biggest impact on the coronavirus pandemic?

How to make a vaccine in record time

Vaccines usually take decades to develop – so how is Oxford University's ChAdOx1 nCoV-1 vaccine trial moving so quickly? It comes down to careful planning, extraordinary logistics and a whole lot of help from partners around the world.

Cookies on this website